Dr. Morgenstern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Certifications & Licensure
- MO State Medical License 2013 - 2026
- CT State Medical License 2010 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Toripalimab for Extensive-Stage Small Cell Lung Cancer.Ayse Ece Cali Daylan, Daniel Morgensztern, Saiama N Waqar
JAMA Oncology. 2025-01-01 - A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Daniel Morgensztern, Neal Ready, Melissa L Johnson, Afshin Dowlati, Noura Choudhury
Clinical Cancer Research. 2024-11-15 - 1 citationsActionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer.Dwight Owen, Rotem Ben-Shachar, Josephine Feliciano, Lisa Gai, Kyle A Beauchamp
JAMA Network Open. 2024-11-04
Press Mentions
- OU Faculty Member Co-Leading Innovative National Trial to Advance Lung Cancer TreatmentDecember 12th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: